Overview

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Status:
Completed
Trial end date:
2021-06-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of the combination of apalutamide plus everolimus at different dose levels.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Aragon Pharmaceuticals, Inc.
Treatments:
Abiraterone Acetate
Everolimus
Sirolimus